Key facts
- Notable investors include ANRI, Globis Capital Partners, ITOCHU Technology Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for OceanusBio
- ·The full record, as it builds
Funding rounds
No funding rounds for OceanusBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OceanusBio
Developer of pharmaceutical products intended to address limited access to innovative medicines. The company focuses on identifying and in-licensing drug candidates from overseas partners, advancing clinical development and regulatory filings, managing manufacturing and quality assurance activities, and coordinating commercialisation planning and collaborations, enabling healthcare providers and patients to obtain additional therapeutic options for unmet medical needs.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2024
- Website
- oceanusbio.jp/
- Ownership
- Privately Held (backing)
OceanusBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OceanusBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OceanusBio in its N-PORT filings yet. We sweep new filings monthly.